These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10498888)

  • 21. Conditional deletion of Rb causes early stage prostate cancer.
    Maddison LA; Sutherland BW; Barrios RJ; Greenberg NM
    Cancer Res; 2004 Sep; 64(17):6018-25. PubMed ID: 15342382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate carcinogenesis and inflammation: emerging insights.
    Palapattu GS; Sutcliffe S; Bastian PJ; Platz EA; De Marzo AM; Isaacs WB; Nelson WG
    Carcinogenesis; 2005 Jul; 26(7):1170-81. PubMed ID: 15498784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
    Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
    Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of probasin-RAS transgenic mice.
    Scherl A; Li JF; Cardiff RD; Schreiber-Agus N
    Prostate; 2004 Jun; 59(4):448-59. PubMed ID: 15065094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bub1 up-regulation and hyperphosphorylation promote malignant transformation in SV40 tag-induced transgenic mouse models.
    Guo C; Wu G; Chin JL; Bauman G; Moussa M; Wang F; Greenberg NM; Taylor SS; Xuan JW
    Mol Cancer Res; 2006 Dec; 4(12):957-69. PubMed ID: 17189386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and role of Foxa proteins in prostate cancer.
    Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
    Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
    Morgenbesser SD; McLaren RP; Richards B; Zhang M; Akmaev VR; Winter SF; Mineva ND; Kaplan-Lefko PJ; Foster BA; Cook BP; Dufault MR; Cao X; Wang CJ; Teicher BA; Klinger KW; Greenberg NM; Madden SL
    Prostate; 2007 Jan; 67(1):83-106. PubMed ID: 17013881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer.
    Leman ES; Madigan MC; Brünagel G; Takaha N; Coffey DS; Getzenberg RH
    J Cell Biochem; 2003 Feb; 88(3):599-608. PubMed ID: 12532335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular markers in the diagnosis of prostate cancer.
    van der Poel HG
    Crit Rev Oncol Hematol; 2007 Feb; 61(2):104-39. PubMed ID: 16945550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic instability-based transgenic models of prostate cancer.
    Voelkel-Johnson C; Voeks DJ; Greenberg NM; Barrios R; Maggouta F; Kurtz DT; Schwartz DA; Keller GM; Papenbrock T; Clawson GA; Norris JS
    Carcinogenesis; 2000 Aug; 21(8):1623-7. PubMed ID: 10910968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies.
    Gabril MY; Duan W; Wu G; Moussa M; Izawa JI; Panchal CJ; Sakai H; Xuan JW
    Mol Ther; 2005 Mar; 11(3):348-62. PubMed ID: 15727931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
    Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
    Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line.
    Masumori N; Tsuchiya K; Tu WH; Lee C; Kasper S; Tsukamoto T; Shappell SB; Matusik RJ
    J Urol; 2004 Jan; 171(1):439-42. PubMed ID: 14665950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
    Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
    Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
    Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo models of prostate cancer metastasis to bone.
    Singh AS; Figg WD
    J Urol; 2005 Sep; 174(3):820-6. PubMed ID: 16093963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
    Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice.
    Lyons SK; Lim E; Clermont AO; Dusich J; Zhu L; Campbell KD; Coffee RJ; Grass DS; Hunter J; Purchio T; Jenkins D
    Cancer Res; 2006 May; 66(9):4701-7. PubMed ID: 16651422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human prostate cancer risk factors.
    Bostwick DG; Burke HB; Djakiew D; Euling S; Ho SM; Landolph J; Morrison H; Sonawane B; Shifflett T; Waters DJ; Timms B
    Cancer; 2004 Nov; 101(10 Suppl):2371-490. PubMed ID: 15495199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.